Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Authors

Subhashis Banerjee (ORCID: https://orcid.org/0000-0001-8971-0006)
Vibeke Strand (ORCID: https://orcid.org/0000-0003-4978-4072)
Marta Mosca (ORCID: https://orcid.org/0000-0001-5937-4574)
Brandon Becker (ORCID: https://orcid.org/0000-0002-9232-631X)
Coburn Hobar (ORCID: https://orcid.org/0009-0006-5935-7997)
Laurent Arnaud (ORCID: https://orcid.org/0000-0002-8077-8394)
Shalabh Singhal
Anca Askanase (ORCID: https://orcid.org/0000-0003-4597-5023)
Jiyoon Choi (ORCID: https://orcid.org/0009-0008-0948-5717)
Samantha Pomponi

Institutions

University of Pisa (IT)
Columbia University Irving Medical Center (US)
Bristol-Myers Squibb (United States) (US)
Bristol-Myers Squibb (Sweden) (SE)
Hôpitaux Universitaires de Strasbourg (FR)
Université de Strasbourg (FR)
Stanford University (US)

Publication Details

Journal: Lupus Science & Medicine
Published: 2025-01-01
DOI: https://doi.org/10.1136/lupus-2025-001517
Citations: 3
Primary Topic: Systemic Lupus Erythematosus Research
Type: article
Field-Weighted Citation Impact: 5.00

Funders

Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Sanofi
Gilead Sciences
Biogen
Alexion Pharmaceuticals
Regeneron Pharmaceuticals
Kiniksa Pharmaceuticals
Celltrion
Servier
Medac
Idorsia Pharmaceuticals
Grifols
Genentech
Samsung
Chugai Pharmaceutical

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Subhashis Banerjee, Vibeke Strand, Marta Mosca, Brandon Becker et al.

Jan 1, 2025

3 citations

Lupus Science & Medicine

Systemic Lupus Erythematosus Research

5.00

article

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Subhashis Banerjee, Vibeke Strand, Marta Mosca, Brandon Becker, Coburn Hobar, Laurent Arnaud, Shalabh Singhal, Anca Askanase, Jiyoon Choi, Samantha Pomponi

January 1, 2025article en

3 citations

Abstract

No abstract available for this paper.

Lupus Science & MedicineVol. 12(1)

University of Pisa (IT), Columbia University Irving Medical Center (US), Bristol-Myers Squibb (United States) (US), Bristol-Myers Squibb (Sweden) (SE), Hôpitaux Universitaires de Strasbourg (FR), Université de Strasbourg (FR), Stanford University (US)

Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Biogen, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Kiniksa Pharmaceuticals, Celltrion, Servier, Medac, Idorsia Pharmaceuticals, Grifols, Genentech, Samsung, Chugai Pharmaceutical

Good health and well-being

Openalex Percentile: Top 5%

Systemic Lupus Erythematosus Research

5.00

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.